Диссертация (1140160), страница 24
Текст из файла (страница 24)
doi: 10.3390/ijms12074465.Epub 2011 Jul 11.97.Carozzi FM, Del Mistro A, Confortini M, et al. Reproducibility of HPV DNATesting by Hybrid Capture 2 in a Screening Setting. Am J Clin Pathol 2005;124:716Y21.98.Carrer A, Wellen KE.// Metabolism and epigenetics: a link cancer cells exploit.//Curr Opin Biotechnol. 2014 Nov 29;34:23-29. doi: 10.1016/j.copbio.2014.11.012. [Epubahead of print]99.Castle PE, Carreon JD.
Practice improvement in cervical screening andmanagement: symposium on management of cervical abnormalities in adolescents and youngwomen. J Low Genit Tract Dis 2010;14:238Y40.100.Castle PE, Fetterman B, Cox JT, et al. The age-specific relationships of abnormalcytology and human papillomavirus DNA results to the risk of cervical precancer and cancer.Obstet Gynecol 2010;116:76Y84.101.Chalertpet K, Pakdeechaidan W, Patel V, Mutirangura A, Yanatatsaneejit P //Human papillomavirus type 16 E7 oncoprotein mediates CCNA1 promotermethylation.//Cancer Sci.
2015 Aug 6. doi: 10.1111/cas.12761.102.Chang CF, Wang M, Fang CY, Chen PL, Wu SF, Chan MW, Chang D. Analysisof DNA methylation in human BK virus. Virus Genes.2011;43:201–207.103.Chang S, Young BD, Li S, Qi X, Richardson JA, Olson EN. Histone deacetylase7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell. 2006;126:321–34104.Chavez-Blanco A, Segura-Pacheco B, Perez-Cardenas E, Taja-Chayeb L, CetinaL, Candelaria M, Cantu D,Gonzalez-Fierro A, Garcia-Lopez P, Zambrano P, Perez-PlasenciaC, Cabrera G, Trejo-Becerril C, Angeles E,Duenas-Gonzalez A.// Histone acetylation andhistone deacetylase activity of magnesium valproate in tumor and peripheral blood of patientswith cervical cancer.
A phase I study. // Mol Cancer. 2005 Jul 7;4(1):22.105.Chen P, Zhao J, Li G. Histone variants in development and diseases. J GenetGenomics. 2013;40:355–365.188106.Chirenje ZM, Rusakaniko S, Akino V, Mlingo M. A randomised clinical trial ofloop electrosurgical excision procedure (LEEP) versus cryotherapy in the treatment of cervicalintraepithelial neoplasia.// J Obstet Gynaecol. 2001 Nov;21(6):617-21.107.Chung YL, Wang AJ, Yao LF (2004). Antitumor histone deacetylase inhibitorssuppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancerradiotherapy.
Mol Cancer Ther. 2004 Mar;3(3):317-25.108.Cohen HY, Lavu S, Bitterman KJ, Hekking B, Imahiyerobo TA, Miller C. et al.Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis.Mol Cell. 2004;13:627–38.109.Cox JT // Management of women with cervical cancer precursor lesions. //Obstet Gynecol Clin North Am. 2002 Dec;29(4):787-816.110.Cuzick J, Clavel C, Petry KU, et al. Overview of the European and NorthAmerican studies on HPV testing in primary cervical cancer screening.
Int J Cancer2006;119:1095Y101.111.Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, WurscherMA, Carter JJ, Porter PL, Galloway DA,McDougall JK. Human papillomavirus, smoking, andsexual practices in the etiology of anal cancer // Cancer. 2004 Jul 15;101(2):270-80.112.Danam RP, Howell SR, Brent TP, Harris LC. // Epigenetic regulation of O6-methylguanineDNA methyltransferase geneexpression by histone acetylation and methylCpG binding proteins.// Mol Cancer Ther. 2005 Jan;4(1):61-9.113.Dawson MA, Kouzarides T.
Cancer epigenetics: from mechanism to therapy.Cell. 2012;150:12–27.114.de Mello Silva MV, Coutinho IC, de Andrade Heráclio S, Fittipaldi HM Jr, KatzL. Factors associated with the persistence/recurrence of CIN2/3 in women submittedto loop electrosurgical excision procedure in a teaching hospital in northeastern Brazil: a casecontrol study.// J Low Genit Tract Dis. 2014 Oct;18(4):286-90.115.De Ruijter A, Van Gennip A, Caron H, Kemp S, van Kuilenburg A. Histonedeacetylases (HDACs): characterization of the classical HDAC family. Biochem J.2003;370:737–749.189116.de Sanjose S, Quint WG, Alemany L, et al.
Human papillomavirus genotypeattribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. LancetOncol 2010;11:1048Y56.117.Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A, Clausse N. et al.Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growthfactor signaling. Oncogene. 2002;21:427–436118.Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytologyand human papillomavirus testing in cervical cancer screening: joint European cohort study.BMJ.
2008;337:a1754.119.Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection amongfemales in the United States. JAMA 2007;297:813Y9.120.Ferrari R, Su T, Li B, Bonora G, Oberai A, Chan Y, Sasidharan R, Berk AJ,Pellegrini M, Kurdistani SK. Reorganization of the host epigenome by a viraloncogene. Genome Res. 2012;22:1212–1221.[PMC free article]121.Filipescu D, Szenker E, Almouzni G.
Developmental roles of histone H3 variantsand their chaperones. Trends Genet. 2013;29(11):630–640.122.Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA. et al.Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.Nature. 1999;401:188–193.123.Finzer P, Kuntzen C, Soto U, et al (2001). Inhibitors of histone deacetylase arrestcell cycle and induce apoptosis in cervical carcinoma cells circumventing humanpapillomavirus oncogene expression.
Oncogene, 20, 4768-76.124.Flannelly G, Bolger B, Fawzi H, De Lopes AB, Monaghan JM.// Follow upafter LLETZ: could schedules be modified according to risk of recurrence?// BJOG. 2001Oct;108(10):1025-30.125.Freeman H, Wingrove B. Excess Cervical Cancer Mortality: A Marker for LowAccess to Health Care in Poor Communities. Rockville, MD: National Cancer Institute; 2005.126.Furumai R, Matsuyama A, Kobashi N, Lee K-H, Nishiyama M, Nakajima H. etal.
FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. CancerRes. 2002;62:4916–4921190127.GładychM, AndrzejewskaA, OleksiewiczU, EstécioMR//Epigeneticmechanisms of induced pluripotency.// Contemp Oncol (Pozn). 2015;19(1A):A30-8. doi:10.5114/wo.2014.47135.128.Gloss BS, Samimi G.// Epigenetic biomarkers in epithelial ovarian cancer.//Cancer Lett. 2014 Jan 28;342(2):257-63.
doi: 10.1016/j.canlet.2011.12.036. Epub 2012 Jan 12.129.Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNAtesting for cervical cancer screening in women aged 30 years or more. Obstet Gynecol 2004;103:619Y31.130.Grant S, Easley C, Kirkpatrick P. Vorinostat. Nat Rev Drug Discov.2007;6:21–131.Gustafsson L, Ponten J, Bergstrom R, Adami HO. International incidence rates of22.invasive cervical cancer before cytological screening.
Int J Cancer 1997;71:159Y65.132.Haberland M, Montgomery RL, Olson EN (The many roles of histonedeacetylases in development and physiology: implications for disease and therapy. Nat RevGenet, 10. - 2009. 32-42.133.HaeryL, ThompsonRC, GilmoreTD//Histone acetyltransferasesand histone deacetylases in B- and T-cell development, physiology and malignancy. //Genes Cancer. 2015 May;6(5-6):184-213.134.Herfs M, Somja J, Howitt BE, Suarez-Carmona M, Kustermans G, HubertP, Doyen J, Goffin F, Kridelka F, Crum CP, Delvenne P. Unique recurrence patterns ofcervical intraepithelial neoplasia after excision of the squamocolumnar junction.// Int JCancer. 2015 Mar 1;136(5):1043-52.
doi: 10.1002/ijc.28978. Epub 2014 Jul 3.135.http://www.cdc.gov/cancer/cervical/. Division of Can- cerPrevention andControl, National Center for Disease Preven- tion and Health Promotion. 2011; accessedJanuary 19, 2012.136.Hu E, Dul E, Sung C-M, Chen Z, Kirkpatrick R, Zhang G-F. et al. Identificationof novel isoform-selective inhibitors within class I histone deacetylases.
J Pharmacol ExpTher. 2003;307:720–728.137.Huo JS, Baylin SB, Zambidis ET// Cancer-like epigenetic derangements ofhuman pluripotent stem cells and their impact on applications in regeneration andrepair. // Curr Opin Genet Dev. 2014 Oct;28:43-9. doi: 10.1016/j.gde.2014.09.008.
Epub2014 Oct 14.191138.JohannsenE,LambertPF.Epigeneticsofhumanpapillomaviruses.Virology. 2013;445:205–212.139.JordanJ, Arbyn M, Martin-HirschP, SchenckU, BaldaufJJ, DaSilvaD, Anttila A, Nieminen P, Prendiville W.// European guidelines for quality assurance incervical cancer screening: recommendations for clinical management of abnormal cervicalcytology, part 1.// Cytopathology. 2008 Dec;19(6):342-54.140.Kallestad L, Woods E, Christensen K, Gefroh A, Balakrishnan L, Milavetz B.Transcription and replication result in distinct epigenetic marks following repression of earlygene expression.
Front Genet.2013;4:140.141.Kato H, Tamamizu-Kato S, Shibasaki F. Histone deacetylase 7 associates withhypoxia-inducible factor 1α and increases transcriptional activity. J Biol Chem.2004;279:41966–41974.142.Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervicalprecancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and thepossible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst2005;97:1072Y9.143.Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of human papillomavirus DNAtesting in the United Kingdom, The Netherlands, France, and Italy. J Natl Cancer Inst 2005;97:888Y95.144.Kjaer SK, Frederiksen K, Munk C ,IftnerT.
Long-term absolute risk of cervicalintraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role ofper- sistence. J Natl Cancer Inst 2010;102:1478Y88.145.Kong X, Lin Z, Liang D, Fath D, Sang N, Caro J. Histone deacetylase inhibitorsinduce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor1alpha. Mol Cell Biol. 2006;26:2019–28.146.Koukoura O, Spandidos DA, Daponte A, Sifakis S. // DNA methylation profilesin ovarian cancer: implication in diagnosis and therapy (Review).
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
